A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 7, Pages e1189051
Publisher
Informa UK Limited
Online
2016-06-01
DOI
10.1080/2162402x.2016.1189051
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination
- (2015) Lisa M. Christian et al. VACCINE
- Modes of action of TLR7 agonists in cancer therapy
- (2014) Sebastian Kobold et al. Immunotherapy
- Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
- (2014) Michele Ardolino et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- (2014) Andrew Davies et al. LANCET ONCOLOGY
- The role of TLR8 signaling in acute myeloid leukemia differentiation
- (2014) J J Ignatz-Hoover et al. LEUKEMIA
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
- (2014) Lorenzo Moretta et al. Frontiers in Immunology
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- Toll-like receptors as therapeutic targets for cancer
- (2013) Johanna Holldack DRUG DISCOVERY TODAY
- Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
- (2013) Chelsea Ma et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
- (2012) Brenda J. Weigel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice
- (2012) S. Belanger et al. BLOOD
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
- (2012) S. Gill et al. BLOOD
- Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
- (2012) S. Adams et al. CLINICAL CANCER RESEARCH
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
- (2012) Nidale Tarek et al. JOURNAL OF CLINICAL INVESTIGATION
- Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer
- (2012) Johannes Falke et al. JOURNAL OF UROLOGY
- Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
- (2011) C. Bourquin et al. CANCER RESEARCH
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- Natural Killer Cells Recognize Friend Retrovirus-Infected Erythroid Progenitor Cells through NKG2D-RAE-1 Interactions In Vivo
- (2011) T. Ogawa et al. JOURNAL OF VIROLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7
- (2009) C. Bourquin et al. JOURNAL OF IMMUNOLOGY
- Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
- (2009) Svetlana Hamm et al. Journal of Immunotoxicology
- A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition
- (2009) Jin Liu et al. MOLECULAR IMMUNOLOGY
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
- (2008) R. Dummer et al. CLINICAL CANCER RESEARCH
- TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN
- (2008) Jon R. Inglefield et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More